Formulation and Development of Transdermal Patches with Antihypertensive Drug

Abstract

Olmesartan medoxomil was found to be water soluble as tested by the vessel shaking method. The formulation P9 had maximum release of all four drugs after 24 hr. However, the tensile strength of P9 batch was the least of all other factorial design batches. Based on Q24 values, batch P9 was selected as optimized batch. Though the tensile strength was low, it was not below the desirable limit. Among P1 to P9 formulations, P9 showed lowest tensile strength, highest % moisture content, % moisture uptake, WVTR and folding endurance. drug loaded patch and gel significantly restored the decreased serum nitric oxide levels compared to to MPA-induced hypertensive rats. On application of Patch (P9) and Patch (P8) restored the NO concentration (67.2 ± 3.7 and 65.3 ± 5.3 μmol/ml). The elevated MDA levels were significantly decreased by the drug loaded patch (P9) and patch (P8) (2.0 ± 0.05 and 2.1 ± 0.02 nmol/ml). The drug loaded patch (P9) and patch (P8) significantly restored the decreased GSH levels (8.9 ± 0.3 and 8.0 ± 0.1 μmol/mL, respectively). Overall, transdermal patches represent a safe, effective, and patient-friendly delivery system for antihypertensive therapy.